Market Cap N/A
Revenue (ttm) 0.00
Net Income (ttm) 0.00
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio N/A
Volume 17,047
Avg Vol N/A
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K N/A
Beta N/A
Analysts Strong Buy
Price Target N/A

Company Profile

Medicus Pharma Ltd., a biotech/life sciences company, focuses on developing clinical development programs of therapeutic assets in the United States. It is developing SKNJCT-003, which is in Phase 2 study for the treatment of basal cell carcinoma of the skin. The company has a strategic collaboration with the Gorlin Syndrome Alliance to access to SKINJECT in Patients with Gorlin Syndrome. The company was formerly known as Interactive Capital Partners Corporation and changed its name to Medicus P...

Phone: 610 636 0184
Address:
300 Conshohocken State Road, Suite 200, West Conshohocken, United States
Latest News on MDCXW
Medicus Pharma submits Protocol SKNJCT-005 to the FDA

2026-06-03T13:37:23.000Z - 4 weeks ago

Medicus Pharma submits Protocol SKNJCT-005 to the FDA


Medicus Pharma Announces $22 Million Non-Dilutive Financing

May 28, 2026, 8:00 AM EDT - 5 weeks ago

Medicus Pharma Announces $22 Million Non-Dilutive Financing


Medicus Pharma reports Q1 EPS (31c), consensus (22c)

2026-05-14T22:18:41.000Z - 7 weeks ago

Medicus Pharma reports Q1 EPS (31c), consensus (22c)


Medicus Pharma initiated with a Buy at Roth Capital

2026-04-21T11:53:55.000Z - 2 months ago

Medicus Pharma initiated with a Buy at Roth Capital


Medicus Pharma submits ODD application to U.S. FDA for SkinJect

2026-04-17T11:35:50.000Z - 2 months ago

Medicus Pharma submits ODD application to U.S. FDA for SkinJect


Medicus Pharma enters media partnership with New to The Street

2026-04-07T14:23:02.000Z - 3 months ago

Medicus Pharma enters media partnership with New to The Street


Medicus Pharma Ltd Clarifies Positive SkinJect Phase 2 Dataset

Apr 1, 2026, 7:30 AM EDT - 3 months ago

Medicus Pharma Ltd Clarifies Positive SkinJect Phase 2 Dataset


Medicus Pharma announces SkinJect Phase 2 KOL update

2026-03-16T11:50:31.000Z - 3 months ago

Medicus Pharma announces SkinJect Phase 2 KOL update


Medicus Pharma announces results from Phase 2 study of D-MNA

2026-03-05T13:10:22.000Z - 4 months ago

Medicus Pharma announces results from Phase 2 study of D-MNA


Medicus Pharma announces results from Phase 2 study of D-MNA

2026-03-05T12:35:46.000Z - 4 months ago

Medicus Pharma announces results from Phase 2 study of D-MNA


Medicus Pharma on Bloomberg World

Feb 12, 2026, 7:30 AM EST - 5 months ago

Medicus Pharma on Bloomberg World


Medicus signs six-part media series with New to the Street

2026-02-10T13:40:50.000Z - 5 months ago

Medicus signs six-part media series with New to the Street


Medicus Pharma announces clinical data on Teverelix

2026-01-12T12:50:08.000Z - 6 months ago

Medicus Pharma announces clinical data on Teverelix


Medicus Pharma Ltd. Enters Into $5.1 Million Warrant Inducement

Dec 5, 2025, 3:20 PM EST - 7 months ago

Medicus Pharma Ltd. Enters Into $5.1 Million Warrant Inducement


Medicus Pharma Ltd. to Present at The Maxim Growth Summit 2025

Oct 13, 2025, 7:30 AM EDT - 9 months ago

Medicus Pharma Ltd. to Present at The Maxim Growth Summit 2025


Medicus Pharma Ltd. To Present at Brookline Capital Markets

Sep 24, 2025, 7:30 AM EDT - 10 months ago

Medicus Pharma Ltd. To Present at Brookline Capital Markets


Medicus Pharma Ltd. Completes Acquisition of Antev Limited

Sep 2, 2025, 7:30 AM EDT - 10 months ago

Medicus Pharma Ltd. Completes Acquisition of Antev Limited